Tiredness on Ozempic, Wegovy, Mounjaro and Zepbound: all four labels list fatigue

Fatigue on each label

Each figure below carries the trial it came from and what the label counted as fatigue, because the four don’t count the same thing.

Zepbound’s row gathers four terms and Wegovy’s two, in different trials, so the two rates can’t be set against each other. The labels themselves say that rates from one drug’s trials “cannot be directly compared” with another’s. The stomach side effects are set out the same way, each with its own trials, on side effect rates, label by label.

Wegovy

In three trials of up to 68 weeks, 11% of adults on Wegovy 2.4 mg reported fatigue, against 5% on placebo. Only headache and five stomach-related reactions were reported more often on Wegovy in that table. The Medication Guide puts “tiredness (fatigue)” on its list of the most common side effects.

The 7.2 mg dose was tested in two 72-week trials against both placebo and 2.4 mg. Fatigue went up with the dose: 5% on placebo, 9% on 2.4 mg and 11% on 7.2 mg.

The trial in patients aged 12 and older lists reactions seen in at least 3% and more often than on placebo, and fatigue isn’t among them. The 25 mg tablet has no fatigue figure of its own; per the label, the common reactions in its trial were “similar to those listed in Table 3”.

Zepbound

Zepbound’s pooled table puts fatigue at 5% on 5 mg, 6% on 10 mg and 7% on 15 mg, against 3% on placebo, in two trials of up to 72 weeks. Each dose step adds a point.

Its row counts four terms: asthenia, fatigue, lethargy and malaise. In the Medication Guide the same entry reads “feeling tired”, one of the most common side effects it lists. Two trials in adults with obstructive sleep apnea reported adverse reactions similar to the weight trials, with no separate fatigue figure.

Ozempic and Mounjaro

Ozempic’s label lists fatigue under “Other adverse reactions with a frequency of >0.4%”, next to dysgeusia and dizziness. That’s a floor, not a rate: fatigue was reported by more than 0.4% of patients, and the label says no more than that. It isn’t on the Medication Guide’s list of the most common side effects.

Mounjaro’s placebo-controlled table lists reactions seen in at least 5% of patients and more often than on placebo, and it has no fatigue row. The one Mounjaro figure comes from SURPASS-CVOT, a heart-outcomes trial in adults with type 2 diabetes and established cardiovascular disease: among 6,647 exposed to Mounjaro, 10% reported fatigue. That trial compared Mounjaro with dulaglutide, another GLP-1 drug, rather than placebo, and the label doesn’t give dulaglutide’s fatigue rate. So 10% says how often fatigue came up, not how much of it the drug caused.

Drowsiness and weakness on the warning lists

All four Medication Guides list “confusion or drowsiness” and “weakness” among the signs of low blood sugar, alongside shakiness, sweating, hunger and a fast heartbeat. Three of them tie the higher risk to taking the drug with another medicine that lowers blood sugar. Ozempic’s reads: “Your risk for getting low blood sugar may be higher if you use OZEMPIC with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin.” Wegovy’s places the risk in patients with type 2 diabetes, especially those also taking insulin or a sulfonylurea.

That’s a separate entry from fatigue, and none of the four labels links the two. Which diabetes medicines each label flags is set out in the drug interactions page. Hair loss, the other side effect people ask about that isn’t a stomach complaint, sits in the same weight-label tables.

Sources

See the providers

Fatigue is a property of the drug, not the seller. The boards list who sells each molecule and what each one publishes.

• Semaglutide providersprovider board

  Compare semaglutide plans, pharmacy details and cancellation terms.

• Tirzepatide providersprovider board

  Compare tirzepatide plans, pharmacy details and cancellation terms.

More, read from the same labels

• First-year GLP-1 costsresearch guide

  A low monthly headline does not tell you what a year of treatment will cost. Compare the same medication and service package, then separate the total you expect to spend from the amount you must pay before treatment begins.

• Cancellation and refundsresearch guide

  Canceling future membership charges, stopping an upcoming medication order and requesting a refund are three different requests. Get a written answer for each one that applies to you.

• Insurance denial documentsresearch guide

  The next step depends on why coverage was denied. A missing document, a formulary restriction and an excluded benefit are different problems. Start with the written decision before paying someone to submit another request.

• Savings and cash-pay eligibilityresearch guide

  A manufacturer savings card and a self-pay offer can have different eligibility rules, even for the same medicine. Match the offer to your coverage and exact product before using its advertised price in your budget.

• Verify your GLP-1 pharmacyresearch guide

  The website taking your payment, the clinician prescribing and the pharmacy dispensing may be different businesses. Identify each one. A recognizable brand or a reassuring badge does not tell you who will fill the prescription.

• Changing GLP-1 providersresearch guide

  Before ending your current service, establish what the new practice needs, what it will charge and when it can evaluate you. Transferring your records does not guarantee that another clinician will continue the same prescription.

• Weight regain after stoppingresearch guide

  Weight regain occurred after treatment withdrawal in studies of semaglutide and tirzepatide. The findings support planning follow-up and affordability before an interruption, but they do not predict exactly what will happen to one person.

• Semaglutide vs tirzepatideresearch guide

  What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.

• How they workresearch guide

  The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.

• Is Ozempic insulin?research guide

  What the Ozempic label calls semaglutide, how that differs from insulin, and where insulin appears on these labels as a separate medicine.

• Zepbound vs Ozempicresearch guide

  Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.

• Dose escalation schedulesresearch guide

  The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.

• Side effect ratesresearch guide

  What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.

• Hair lossresearch guide

  Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.

• Missed dose rulesresearch guide

  The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.

• Drug interactionsresearch guide

  Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.

• Buying one onlineresearch guide

  The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.

• Zepbound by doseresearch guide

  What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.

• Zepbound at 3 monthsresearch guide

  What does the Zepbound label report about three-month weight loss and maintenance dosing?

• Injecting tirzepatideresearch guide

  The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.

• Refrigeration and storageresearch guide

  How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.

• Who should not take oneresearch guide

  The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.